tm logo
Trademark Search
HYBRID CONCEPTS INTERNATIONAL
HYBRID CONCEPTS INTERNATIONAL
SEARCHED

on 08 Dec 2023

Last Applicant/ Owned by

HYBRID CONCEPTS INTERNATIONAL LLC

2135 BEDELL ROAD, SUITE 9BGRAND ISLAND NY 14072

US

Serial Number

2205961 filed on 06th Jun 2022

Correspondent Address

SUITE 2600, 160 ELGIN STREETOTTAWA

ONTARIO

CA

K1P1C3

HYBRID CONCEPTS INTERNATIONAL

Vienna Information


1 . 13 . 1

Armillary spheres, planetaria, astronomic orbits, atomic models, molecular modelsSphères armillaires, planétariums, orbites astronomiques, schémas d'atomes, schémas de molécules

1 . 13 . 15

Atomic models, molecular models, representations of human, animal or vegetal cells, images of bacteria or viruses, DNA helixesSchémas atomiques, schémas de molécules, représentations de cellules humaines, animales ou végétales, images de bactéries ou de virus, hélices d'ADN

27 . 3 . 1

Letters or numerals representing a human being or a part of the human body, an animal or a part of an animal's body, a plant, a heavenly body, a natural phenomenon or an objectLettres ou chiffres représentant un être humain ou une partie du corps humain, un animal ou une partie du corps d'un animal, un végétal, un corps céleste, un phénomène naturel ou un objet

27 . 3 . 12

Letters or numerals representing a heavenly body or a natural phenomenonLettres ou chiffres représentant un corps céleste ou un phénomène naturel

27 . 5 . 1

Letters presenting a special form of writingLettres présentant un graphisme spécial

27 . 5 . 2

Letters written in double outlineLettres avec un contour double

Trademark usage description

assistance, advisory services and consultancy with regard to business planning; business consulting and management in the field of clinical trials, na Read More

Classification Information


Class [035]
Assistance, advisory services and consultancy with regard to business planning; business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; business consulting services; business consulting services in the field of potential medical cures including cell and gene therapies; business consultation in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, regulatory affairs including preclinical, clinical and commercial stage, pharmaceutical preclinical and clinical research, development, chemistry, manufacturing and controls, and quality assurance/quality control; business consulting services, namely, providing assistance in development of business strategies and creative ideation; business management consulting and advisory services; business support services, namely, business consulting to freelancers, start-ups, existing businesses and non-profit organizations; consultancy and advisory services in the field of business strategy; consulting services in the field of medical product approval for commercial purposes; international business consulting services relating to USA and outside of USA product, clinical and commercial development of investigational or approved medical products; new business venture development and formation consulting services; promoting the exchange of information and resources within the scientific research communities to achieve advances in the field of 21st century transformational science; providing consulting services in the field of regulatory submission management to medical companies to assist them with applications for medical device approval; providing independent review of clinical trials for business purposes; promoting technical and scientific investigation, research and experimentation in the field of scientific discovery through support of educational institutions and scientific organizations.


Classification kind code

11

Class [036]
Financial consulting services, namely, advising others regarding intellectual property investments; investment consultation in the fields of product, technical, regulatory, preclinical, clinical, and commercial diligence for innovative potential or investigational medical products.


Classification kind code

11

Class [042]
Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; medical and scientific research information in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, regulatory affairs including preclinical, clinical and commercial stage, pharmaceutical preclinical and clinical research, development, manufacturing/CMC and quality assurance/quality control; providing information about medical and scientific research; providing information on the subject of scientific research in the field of biochemistry and biotechnology; providing medical and scientific research information in the field of clinical trials; providing medical and scientific research information in the fields of pharmaceuticals and genetics; scientific and technological services, namely, scientific research in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, scientific research for preclinical, clinical and commercial stage pharmaceuticals, pharmaceutical preclinical and clinical research, development, and quality assurance/quality control; scientific research consulting in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, scientific research for preclinical, clinical and commercial stage pharmaceuticals, pharmaceutical preclinical and clinical research, development, and quality assurance/quality control; scientific research and development; technological planning and consulting services in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, scientific research for preclinical, clinical and commercial stage pharmaceuticals, pharmaceutical preclinical and clinical research, development, and quality assurance/quality control; testing, inspection, research, or development of pharmaceutical preparations for gene therapy; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; scientific consulting and research services relating to foods and dietary supplements; scientific research consulting in the field of cosmetics.


Classification kind code

11

Class [044]
Consulting services in the field of health; consulting services to health care providers in the field of treating life-changing or life-threatening diseases.


Classification kind code

11

Mark Details


Serial Number

2205961

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 22
on 08th Dec 2023
Search Recorded
Submitted for opposition 20
on 08th Dec 2023
Examiner's First Report
Submitted for opposition 223
on 08th Dec 2023
Total Provisional Refusal
Submitted for opposition 236
on 06th Oct 2023
Partial Withdrawal - Madrid Protocol
Submitted for opposition 256
on 26th Jun 2023
Notification of Possible Opposition Sent
Submitted for opposition 257
on 25th Aug 2022
Designation Notification - Madrid Protocol
Submitted for opposition 31
on 24th Aug 2022
Formalized
Submitted for opposition 1
on 24th Aug 2022
Created
Submitted for opposition 228
on 06th Jun 2022
International Registration
Submitted for opposition 30
on 06th Jun 2022
Filed